help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on June 15, 2006, doi:10.1165/rcmb.2005-0207OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-0207OCv1
35/5/540    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, Y.-P.
Right arrow Articles by Chu, Y.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, Y.-P.
Right arrow Articles by Chu, Y.-H.
American Journal of Respiratory Cell and Molecular Biology. Vol. 35, pp. 540-548, 2006
© 2006 American Thoracic Society
DOI: 10.1165/rcmb.2005-0207OC

Identification of a 4-mer Peptide Inhibitor that Effectively Blocks the Polymerization of Pathogenic Z {alpha}1-Antitrypsin

Yi-Pin Chang, Ravi Mahadeva, Wun-Shaing W. Chang, Anshuman Shukla, Tim R. Dafforn and Yen-Ho Chu

Department of Chemistry and Biochemistry, National Chung Cheng University, Chia-Yi; Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan, R.O.C.; Department of Medicine, University of Cambridge, Cambridge; and Department of Biosciences, University of Birmingham, Birmingham, United Kingdom

Correspondence and requests for reprints should be addressed to Yen-Ho Chu, Department of Chemistry and Biochemistry, National Chung Cheng University, 168 University Rd., Min-Hsiung, Chia-Yi, Taiwan 62102, R.O.C. E-mail: cheyhc{at}ccu.edu.tw

{alpha}1-Antitrypsin (AT) is a major proteinase inhibitor within the lung. The Z variant of AT (E342K) polymerizes within the liver and lung, resulting in hepatic aggregation of AT and tissue deficiency, predisposing to early onset of cirrhosis and emphysema, respectively. Polymerization of the aberrant protein can be prevented in vitro by specific peptides such as FLEAIG. This peptide serves as a lead molecule to design a shorter peptide that may be effective as a therapeutic agent. In this study we employed a systematic chemical approach using alanine scanning of Ac-FLEAIG-OH and subsequent peptide shortening to study the binding of shorter peptides to Z-AT. While two additional 6-mer peptides Ac-FLAAIG-OH and Ac-FLEAAG-OH were found to bind to Z-AT, their daughter peptides Ac-FLEAA-NH2 and Ac-FLAA-NH2 also bound avidly to Z-AT and prevented polymerization of the protein. Further comparative studies revealed that the binding of Ac-FLAA-NH2 was more specific for Z-AT. The peptide–AT complex formation was enhanced by the presence of C-terminal amide group on the peptide, and circular dichroism analysis demonstrated that a random coil rather than a beta-helical conformation favored binding of the peptide to AT. In summary, this study has identified novel small peptides that inhibit Z-AT polymerization, and are a significant advance towards the treatment of Z-AT–related cirrhosis and emphysema.

Key Words: {alpha}1-antitrypsin • {alpha}1-proteinase inhibitor • alanine scanning • polymerization • serpin







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2006 American Thoracic Society.